Madison Investment Holdings Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 241,625 shares of the biopharmaceutical company’s stock after buying an additional 8,520 shares during the period. Madison Investment Holdings Inc.’s holdings in Gilead Sciences were worth $16,411,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Peapack Gladstone Financial Corp raised its stake in Gilead Sciences by 69.8% in the first quarter. Peapack Gladstone Financial Corp now owns 12,318 shares of the biopharmaceutical company’s stock valued at $837,000 after buying an additional 5,062 shares during the last quarter. Buckingham Capital Management Inc. raised its stake in Gilead Sciences by 7.0% in the first quarter. Buckingham Capital Management Inc. now owns 19,539 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 1,280 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. raised its stake in Gilead Sciences by 4.8% in the first quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 7,880 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 360 shares during the last quarter. RPG Investment Advisory LLC raised its stake in Gilead Sciences by 16.1% in the first quarter. RPG Investment Advisory LLC now owns 87,585 shares of the biopharmaceutical company’s stock valued at $5,947,000 after buying an additional 12,116 shares during the last quarter. Finally, Pacer Advisors Inc. raised its stake in Gilead Sciences by 11.4% in the first quarter. Pacer Advisors Inc. now owns 45,361 shares of the biopharmaceutical company’s stock valued at $3,081,000 after buying an additional 4,651 shares during the last quarter. 74.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 73.16 on Monday. The company’s 50-day moving average price is $70.60 and its 200-day moving average price is $68.59. The company has a market capitalization of $95.55 billion, a PE ratio of 7.95 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period in the previous year, the firm earned $3.08 earnings per share. The company’s revenue was down 8.2% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

COPYRIGHT VIOLATION WARNING: “Madison Investment Holdings Inc. Has $16.41 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/madison-investment-holdings-inc-has-16-41-million-stake-in-gilead-sciences-inc-nasdaqgild.html.

Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Friday, July 28th. Cowen and Company reiterated an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the transaction, the director now directly owns 47,562 shares in the company, valued at $3,198,544.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 216,609 shares of company stock worth $15,891,851. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.